Anti-Cancer Pill Shows Promising Results in Human Experiment

Researchers at the Peter MacCallum Cancer Center in Australia have found that a drug called divarasib, when combined with another treatment called cetuximab, shows promising results in treating a specific form of bowel cancer caused by a mutation in the KRAS gene. The combination resulted in a positive outcome for 62 percent of patients, with tumors either completely eradicated or reduced in size. The drug is 20 times more effective than other treatments targeting the same cancer and has manageable side effects.